CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014

CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress 
and Present at the Biotech Showcase 2014 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 01/07/14 --  CytoSorbents
Corporation (OTCBB: CTSO), a critical care immunotherapy company,
announced that it will exhibit its CytoSorb(R) and HemoDefend(TM)
technologies at the Society of Critical Care Medicine (SCCM) 43rd
Critical Care Congress from January 10-12, 2014 at the Moscone Center
South in San Francisco, California in Booth 918. More than 4,000
critical care clinicians from the U.S. and abroad are expected to
attend. 


 
--  CytoSorb(R) is the only specifically approved extracorporeal
    cytokine filter in the European Union. It is clinically proven to
    reduce excessive blood levels of cytokines, often called "cytokine
    storm", which can drive dangerous and deadly widespread inflammation
    in critically ill patients. This uncontrolled inflammation can rapidly
    lead to the damage and failure of vital organs, the cause of nearly
    half of all deaths in the intensive care unit (ICU). The goal of
    CytoSorb(R) therapy is to prevent or treat organ failure by
    reducing severe inflammation in a diverse set of life threatening
    conditions such as sepsis, lung injury, trauma, burn injury,
    pancreatitis and others. CytoSorb(R) is commercially available in
    multiple European and Asian countries.
    
    
--  HemoDefend(TM) - Currently under advanced development,
    HemoDefend(TM) is designed to improve the quality and safety of the
    blood supply by removing non-infectious contaminants such as free
    hemoglobin, cytokines, bioactive lipids, and antibodies from stored
    blood products. Many of these contaminants accumulate during blood
    storage and can cause transfusion reactions and adverse outcomes,
    including death, in recipients. Critically ill patients, those
    undergoing high risk surgery such as cardiac surgery, and those
    receiving multiple blood transfusions such as trauma patients are at
    particularly high risk for problems. HemoDefend(TM) is configured as
    either an in-line point of transfusion filter or as a novel
    "Beads-in-a-bag" blood storage bag.

  
Dr. Phillip Chan, MD, PhD, Chief Executive Officer, stated "The initial
feedback on our technologies from intensive care unit physicians in
the U.S. has been very positive. As we look to expand our CytoSorb(R)
clinical trial activity in the U.S., our goal is to generate even
greater awareness amongst a larger universe of physicians and to
convey how many of their European counterparts are already using
CytoSorb(R) for multiple ICU applications."  
In addition, Dr. Chan will also present at the Biotech Showcase(TM)
2014 conference on Wednesday, January 15, 2014 in San Francisco. The
presentation will take place at 4:00 PM PST in Room Mission II of the
Parc 55 Wyndham San Francisco Hotel. Dr. Chan will provide an
overview and update on the Company's current status and plans for
2014. He will be joined by Kathleen Bloch, Chief Financial Officer,
and Chris Cramer, Vice President of Business Development during the
informal question and answer session that will follow. A copy of the
presentation will be posted to the Company's website following the
conference. 
CytoSorb(R) and HemoDefend(TM) are not yet United States FDA
approved. 
About SCCM 
The Society of Critical Care Medicine (SCCM) is a non-profit
organization that represents nearly 16,000 highly trained
professionals in more than 100 countries whose collective goal is to
secure the highest quality care for all critically ill and injured
patients. The SCCM envisions a day when all such patients are cared
for by a dedicated team of physicians, nurses, and other medical
professionals specifically trained in critical care. The organization
publishes Critical Care Medicine, the premier peer-reviewed,
scientific journal in critical care, as well as Pediatric Critical
Care Medicine, the first scientific, peer-reviewed journal to focus
exclusively on pediatric and neonatal critical care.  
About Biotech Showcase(TM) 
Biotech Showcase(TM) 2014 is one of the industry's largest annual
healthcare investor and partnering conferences, with more than 1,700
attendees expected. Attendees include biopharmaceutical and life
science company executives, investors in private and public
companies, sector analysts, bankers and industry professionals. The
conference is run concurrently with, but independently from, the JP
Morgan Healthcare Conference in San Francisco, one of the largest and
most influential international healthcare conferences. Now in its
sixth year, the Biotech Showcase(TM) features multiple tracks of
presenting companies, plenary sessions, workshops, networking, and an
opportunity to schedule one-to-one meetings. Biotech Showcase is
produced by Demy Colton Life Science Advisors and EBD Group. 
About CytoSorbents Corporation  
CytoSorbents is a critical care focused immunotherapy company using
blood purification to modulate inflammation -- with the goal of
preventing or treating multiple organ failure in life-threatening
illnesses. Organ failure is the cause of nearly half of all deaths in
the intensive care unit, with little to improve clinical outcome.
CytoSorb(R), the Company's flagship product, is approved in the
European Union as a safe and effective extracorporeal cytokine
filter, designed to reduce the "cytokine storm" that could otherwise
cause massive inflammation, organ failure and death in common
critical illnesses such as sepsis, burn injury, trauma, lung injury,
and pancreatitis. These are conditions where the risk of death is
extremely high, yet no effective treatments exist. CytoSorbents'
purification technologies are based on biocompatible, highly porous
polymer beads that can actively remove toxic substances from blood
and other bodily fluids by pore capture and surface adsorption.
CytoSorbents has numerous products under development based upon this
unique blood purification technology, protected by 32 issued US
patents and multiple applications pending, including HemoDefend(TM),
ContrastSorb, DrugSorb, and others. Additional information is
available for download on the Company's website:
http://www.cytosorbents.com/ 
Forward-Looking Statements
 This press release includes
forward-looking statements intended to qualify for the safe harbor
from liability established by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press release
are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ
materially from those anticipated. These statements are based on
management's current expectations and assumptions and are naturally
subject to uncertainty and changes in circumstances. We caution you
not to place undue reliance upon any such forward-looking statements.
Actual results may differ materially from those expressed or implied
by the statements herein. Risk factors are detailed in the Company's
Form 10-K filed with the SEC on April 3, 2013, which is available at
http://www.sec.gov. 
Company Contact: 
CytoSorbents Corporation
Dr. Phillip Chan, MD, PhD
Chief Executive Officer 
(732) 329-8885 ext. *823
pchan@cytosorbents.com 
Investor Contact: 
CytoSorbents Corporation
Amy Vogel
(732) 329-8885 ext. *777
avogel@cytosorbents.com 
 
 
Press spacebar to pause and continue. Press esc to stop.